Lv1
80 积分 2023-01-19 加入
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
12小时前
待确认
In vivo dendritic cell reprogramming for cancer immunotherapy
1个月前
已完结
Genome-wide association analyses define pathogenic signaling pathways and prioritize drug targets for IgA nephropathy
3个月前
已完结
Nectin-4-directed antibody-drug conjugates (ADCs): Spotlight on preclinical and clinical evidence
3个月前
已完结
From bench to bedside: targeting lymphocyte activation gene 3 as a therapeutic strategy for autoimmune diseases
5个月前
已完结
An atlas of transcribed enhancers across helper T cell diversity for decoding human diseases
5个月前
已完结
Development of ICT01, a first-in-class, anti-BTN3A antibody for activating Vγ9Vδ2 T cell–mediated antitumor immune response
5个月前
已完结
IL-10-expressing CAR T cells resist dysfunction and mediate durable clearance of solid tumors and metastases
5个月前
已完结
Human anti-PSCA CAR macrophages possess potent antitumor activity against pancreatic cancer
6个月前
已完结
Promising novel siRNA for the treatment of hypertension
6个月前
已完结
皖公网安备34019202002308
